IL22 and type 2 diabetes mellitus: Recombinant IL-22 treatment reduced the secretion of neutrophil elastase 2 by epithelial cell-associated neutrophils, which is known to damage epithelial cell lining in the lungs of Mtb-infected T2DM mice.